In vivo evaluation of intestinal human CYP3A inhibition by macrolide antibiotics in CYP3A-humanised mice

References

• Abduljalil, K., et al., 2009. Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. Antimicrobial agents and chemotherapy, 53 (7), 2892–2901.
   PubMed Web of Science ®Google Scholar
• Abe, S., et al., 2017. Modification of single-nucleotide polymorphism in a fully humanised CYP3A mouse by genome editing technology. Scientific reports, 7 (1), 15189.
   PubMedGoogle Scholar
• Abu-Gharbieh, E., et al., 2004. Antibacterial macrolides: a drug class with a complex pharmacological profile. Pharmacological research, 50 (3), 211–222.
   PubMed Web of Science ®Google Scholar
• Aueviriyavit, S., Kobayashi, K., and Chiba, K., 2010. Species differences in mechanism-based inactivation of CYP3A in humans, rats and mice. drug metabolism and pharmacokinetics, 25 (1), 93–100.
   PubMed Web of Science ®Google Scholar
• Bartkowski, R.R., et al., 1989. Inhibition of alfentanil metabolism by erythromycin. Clinical pharmacology and therapeutics, 46 (1), 99–102.
   PubMed Web of Science ®Google Scholar
• Drozdzik, M., et al., 2018. Protein abundance of clinically relevant drug-metabolizing enzymes in the human liver and intestine: a comparative analysis in paired tissue specimens. Clinical pharmacology & therapeutics, 104 (3), 515–524.
   PubMed Web of Science ®Google Scholar
• Eberts, F.S., et al., 1981. Triazolam disposition. Clinical pharmacology and therapeutics, 29 (1), 81–93.
   PubMed Web of Science ®Google Scholar
• Ernest, C.S., Hall, S.D., and Jones, D.R., 2005. Mechanism-based inactivation of CYP3A by HIV protease inhibitors. Journal of pharmacology and experimental therapeutics, 312 (2), 583–591.
   PubMed Web of Science ®Google Scholar
• Franklin, R.M., 1991. Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds. Methods in enzymology, 206, 559–573.
   PubMed Web of Science ®Google Scholar
• Guengerich, P.F., 1999. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual review of pharmacology and toxicology, 39 (1), 1–17.
   PubMed Web of Science ®Google Scholar
• Henderson, C.J., et al., 2019. An extensively humanised mouse model to predict pathways of drug disposition and drug/drug interactions, and to facilitate design of clinical trials. Drug metabolism and disposition, 47 (6), 601–615.
   PubMed Web of Science ®Google Scholar
• Jaiswal, S., et al., 2014. Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanised" animal models. Drug metabolism reviews, 46 (4), 475–493.
   PubMed Web of Science ®Google Scholar
• Kazuki, Y., et al., 2013. Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. Human molecular genetics, 22 (3), 578–592.
   PubMed Web of Science ®Google Scholar
• Kazuki, Y., et al., 2019. Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism. Proceedings of the National Academy of Sciences, 116 (8), 3072–3081.
   PubMed Web of Science ®Google Scholar
• Kobayashi, K., et al., 2019. CYP3A4 induction in the liver and intestine of pregnane X receptor/CYP3A-humanised mice: approaches by mass spectrometry imaging and portal blood analysis. Molecular pharmacology, 96 (5), 600–608.
   PubMed Web of Science ®Google Scholar
• Liu, L., et al., 2012. Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR. Biopharmaceutics & drug disposition, 33 (4), 207–217.
   PubMed Web of Science ®Google Scholar
• Minegishi, G., et al., 2019. Comparison of the hepatic metabolism of triazolam in wild-type and Cyp3a-knockout mice for understanding CYP3A-mediated metabolism in CYP3A-humanised mice in vivo. Xenobiotica, 49 (11), 1303–1310.
   PubMed Web of Science ®Google Scholar
• Naritomi, Y., Sanoh, S., and Ohta, S., 2018. Chimeric mice with humanised liver: Application in drug metabolism and pharmacokinetics studies for drug discovery. Drug metabolism and pharmacokinetics, 33 (1), 31–39.
   PubMed Web of Science ®Google Scholar
• Nitta, S., et al., 2018. Evaluation of 4β-hydroxycholesterol and 25-hydroxycholesterol as endogenous biomarkers of CYP3A4: study with CYP3A-humanised mice. The AAPS journal, 20 (3), 61.
   PubMedGoogle Scholar
• Ogasawara, A., et al., 2009. In vivo evaluation of drug-drug interaction via mechanism-based inhibition by macrolide antibiotics in cynomolgus monkeys. Drug Metabolism and Disposition, 37 (11), 2127–2136.
   PubMed Web of Science ®Google Scholar
• Okudaira, T., et al., 2007. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. The journal of clinical pharmacology, 47 (7), 871–876.
   PubMed Web of Science ®Google Scholar
• Perloff, M.D., et al., 2000. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. The journal of pharmacology and experimental therapeutics, 292 (2), 618–628.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont, T., et al., 2013. Drug-drug interaction studies: regulatory guidance and an industry perspective. The AAPS journal, 15 (3), 629–645.
   PubMed Web of Science ®Google Scholar
• Qiu, S., and Zhong, X., 2017. Macrolides: a promising pharmacologic therapy for chronic obstructive pulmonary disease. Therapeutic advances in respiratory disease, 11 (3), 147–155.
   PubMed Web of Science ®Google Scholar
• Rubinstein, E., 2001. Comparative safety of the different macrolides. International journal of antimicrobial agents, 18 (Suppl 1), 71–76.
   PubMedGoogle Scholar
• Sampson, M.R., et al., 2019. Dosing recommendations for quetiapine when coadministered with HIV protease inhibitors. The journal of clinical pharmacology, 59 (4), 500–509.
   PubMed Web of Science ®Google Scholar
• Satoh, D., et al., 2018. Human and mouse artificial chromosome technologies for studies of pharmacokinetics and toxicokinetics. Drug metabolism and pharmacokinetics, 33 (1), 17–30.
   PubMed Web of Science ®Google Scholar
• Tseng, E., et al., 2014. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide). Drug metabolism and disposition, 42 (7), 1163–1173.
   PubMed Web of Science ®Google Scholar
• Tsunoda, S.M., et al., 1999. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clinical pharmacology & therapeutics, 66 (5), 461–471.
   PubMed Web of Science ®Google Scholar
• van Waterschoot, R.A., et al., 2009. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanised CYP3A4 transgenic mice using triazolam. Drug metabolism and disposition, 37 (12), 2305–2313.
   PubMed Web of Science ®Google Scholar
• Yasuda, K., et al., 2008. A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug metabolism and disposition, 36 (8), 1689–1697.
   PubMed Web of Science ®Google Scholar
• Yu, J., et al., 2018. Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016. Drug metabolism and disposition, 46 (6), 835–845.
   PubMed Web of Science ®Google Scholar